Skip to main content

Table 2 Comparison of median doses (interquartile range) in the six months prior to and six months after inflammatory disease therapy initiation

From: Claims for disease-modifying therapy by Alberta non-insured health benefits clients

 

Acetaminophen

NSAIDsa

Opioidsb

Corticosteroidsc

DMARDs Only (Incident to database after 2002)

n = 456

Pre: 180.6 mg

(88.9–500)

Post: 277.8 mg (88.9–666.7)

(p = 0.7)

Pre: 455.6 mg (216.7–866.7)

Post: 547.9 mg (233.3–1067.7)

(p = 0.02)

Pre: 3.3 mg

(1.1–9.4)

Post: 3.4 mg

(0.8–14.0)

(p = 0.08)

Pre: 6.2 mg

(1.8–11.4)

Post: 5.3 mg

(2.1–13.7)

(p = 0.7)

Biologic Usersd

n = 229

Pre: 277.8 mg (166.7–833.3)

Post: 277.8 mg (83.3–555.6)

(p = 0.5)

Pre: 600.0 mg (305.3–1200.0)

Post: 633.3 mg (300.0–1333.3)

(p = 0.2)

Pre: 18.0 mg

(5.0–56.1)

Post: 22.3 mg

(7.4–58.4)

(p = 0.04)

Pre: 5.0 mg

(1.75–10.0)

Post: 5.8 mg

(2.1–10.6)

(p = 0.02)

  1. amg of ibuprofen equivalent
  2. bmg of morphine equivalent
  3. cmg of prednisone equivalent
  4. dIncludes patients with data available for 6 months prior to and following biologic initiation